Q-omics provides the consensus-scored TMEM52 profile across patient tissues and cancer cell-line models. TMEM52 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TMEM52 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TMEM52 RNA expression shows 15,384 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UCEC, COAD, and PDAC as cancer lineages where TMEM52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM52 survival associations across molecular data types. TMEM52 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM52 RNA expression–survival associations across cancer types. High TMEM52 expression shows unfavorable associations in UCEC, COAD, UVM, KICH and PAAD, but favorable associations in LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for TMEM52 RNA expression.
This table summarizes TMEM52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM52 shows lower tumor expression in KIRP and THCA and higher tumor expression in COAD, LUAD, LUSC and BLCA. The COAD box plot shows higher TMEM52 RNA expression in tumor versus normal tissue (log2 FC = +1.447, t-test p < 0.001).
This table shows molecular features associated with TMEM52 in patient tissues and cancer cell lines. In patient samples, TMEM52 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
